Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19

Blood Adv. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326.

José Luis Piñana^{1

2}, Ramon Garcia-Sanz³, Rodrigo Martino⁴, María Garcia-Roa⁵, Gabriel Andrés Martin-Martin³, Irene Risco-Gálvez⁶, Mar Tormo^{1

2}, Pilar Martinez-Barranco⁵, Sara Marcos-Corrales³, Marisa Calabuig^{1

2}, Venancio Conesa⁷, Anabel Teruel^{1

2}, Sara Ruiz-Pérez⁸, Carlos Solano^{1

2}, David Navarro^{2

9}, Ángel Cedillo¹⁰, Anna Sureda¹¹

¹ Hematology Department and.
² Fundación INCLIVA, Instituto de Investigación Sanitaria, Hospital Clínico Universitario de Valencia, Valencia, Spain.
³ Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain.
⁴ Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁵ Hematology Division, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
⁶ Hematology Division, Hospital Arnau de Vilanova, Valencia, Spain.
⁷ Hematology Division, Hospital General Universitari d'Elx, Elche, Spain.
⁸ Hematology Division, Hospital Ramón y Cajal, Madrid, Spain.
⁹ Microbiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
¹⁰ Hematopoietic Stem Cell Transplantation and Cell Therapy Group, Madrid, Spain; and.
¹¹ Hematology Division, Institut Català Oncologia-Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.

No abstract available

MeSH terms